Trial Outcomes & Findings for PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors (NCT NCT00819780)

NCT ID: NCT00819780

Last Updated: 2022-12-06

Results Overview

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

• Recruitment status: COMPLETED
• Study phase: PHASE2
• Target enrollment: 285 participants
• Primary outcome timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.
• Results posted on: 2022-12-06

Participant Flow

First patient was enrolled on 24 April 2009; last patient was enrolled on 09 December 2011.

Participant milestones

Measure	Panitumumab Plus mFOLFOX6 Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2) and 5-fluorouracil (5-FU; 2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.	Bevacizumab Plus mFOLFOX6 Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2), followed by 5-FU (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Overall Study STARTED	142	143
Overall Study Received Study Treatment	139	139
Overall Study COMPLETED	114	122
Overall Study NOT COMPLETED	28	21

Reasons for withdrawal

Measure	Panitumumab Plus mFOLFOX6 Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and modified FOLFOX6 (mFOLFOX6) chemotherapy regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2) and 5-fluorouracil (5-FU; 2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.	Bevacizumab Plus mFOLFOX6 Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 regimen consisting of oxaliplatin (85 mg/m\^2), leucovorin (400 mg/m\^2), followed by 5-FU (2400 mg/m\^2) administered on Day 1 of every 14-day cycle until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Overall Study Did not receive study drug	3	4
Overall Study Still in treatment	25	17

Baseline Characteristics

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Baseline characteristics by cohort

Measure	Panitumumab Plus mFOLFOX6 n=142 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=143 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Total n=285 Participants Total of all reporting groups
Age, Continuous	61.6 years STANDARD_DEVIATION 10.4 • n=5 Participants	60.5 years STANDARD_DEVIATION 9.8 • n=7 Participants	61.0 years STANDARD_DEVIATION 10.1 • n=5 Participants
Sex: Female, Male Female	56 Participants n=5 Participants	47 Participants n=7 Participants	103 Participants n=5 Participants
Sex: Female, Male Male	86 Participants n=5 Participants	96 Participants n=7 Participants	182 Participants n=5 Participants
Race/Ethnicity, Customized White or Caucasian	131 participants n=5 Participants	127 participants n=7 Participants	258 participants n=5 Participants
Race/Ethnicity, Customized Black or African American	9 participants n=5 Participants	6 participants n=7 Participants	15 participants n=5 Participants
Race/Ethnicity, Customized Hispanic or Latino	2 participants n=5 Participants	5 participants n=7 Participants	7 participants n=5 Participants
Race/Ethnicity, Customized Asian	0 participants n=5 Participants	4 participants n=7 Participants	4 participants n=5 Participants
Race/Ethnicity, Customized Japanese	0 participants n=5 Participants	1 participants n=7 Participants	1 participants n=5 Participants
Prior Adjuvant Oxaliplatin Therapy Yes	14 participants n=5 Participants	14 participants n=7 Participants	28 participants n=5 Participants
Prior Adjuvant Oxaliplatin Therapy No	128 participants n=5 Participants	129 participants n=7 Participants	257 participants n=5 Participants
RAS and BRAF Mutation Status BRAF wild-type	103 participants n=5 Participants	108 participants n=7 Participants	211 participants n=5 Participants
RAS and BRAF Mutation Status RAS Wild-type	88 participants n=5 Participants	82 participants n=7 Participants	170 participants n=5 Participants
RAS and BRAF Mutation Status RAS/BRAF wild-type	77 participants n=5 Participants	79 participants n=7 Participants	156 participants n=5 Participants
RAS and BRAF Mutation Status Testing not performed	13 participants n=5 Participants	18 participants n=7 Participants	31 participants n=5 Participants
RAS and BRAF Mutation Status Sample acceptance failure	8 participants n=5 Participants	7 participants n=7 Participants	15 participants n=5 Participants

PRIMARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Intent-to-treat (ITT) analysis set (all randomized participants)

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=142 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=143 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Progression-free Survival (PFS)	10.9 months Interval 9.4 to 13.0	10.1 months Interval 9.0 to 12.6

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Intent-to-treat analysis set

Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=142 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=143 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Overall Survival	NA months Interval 28.8 to Not estimable due to the low number of events	25.4 months Interval 22.9 to 29.5

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Evaluable for Local Tumor Response Analysis Set, defined as the subset of participants in the ITT Analysis Set who had at least 1 unidimensionally measurable lesion per modified RECIST 1.0 per the local investigator.

Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=142 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=142 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Percentage of Participants With an Objective Response	57.75 percentage of participants Interval 49.18 to 65.98	53.52 percentage of participants Interval 44.97 to 61.93

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Evaluable for Local Tumor Response Analysis Set: Responders

For participants with a confirmed objective response, the time from first confirmed objective response to radiologic disease progression per modified RECIST 1.0 criteria or death. For participants who responded and have not progressed or died, duration of response was censored at their last evaluable disease assessment date.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=82 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=76 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Duration of Response	10.0 months Interval 8.4 to 12.9	9.0 months Interval 7.4 to 9.5

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Intent-to-treat analysis set

Time to progression (TTP) is defined as the time from randomization to the date of radiologic disease progression per modified RECIST 1.0 criteria. Participants not meeting criteria for disease progression by the analysis data cutoff date were censored at their last evaluable disease assessment date. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=142 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=143 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Time to Disease Progression	11.0 months Interval 9.7 to 13.1	11.1 months Interval 9.3 to 12.7

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Evaluable for Local Tumor Response Analysis Set: Responders

For participants with a confirmed objective response, the time from randomization to the date of first confirmed objective response. Assessments are based on the investigator's review of scans using a modified-RECIST v1.0. An objective response is defined as a best tumor response of complete or partial response. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=82 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=76 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Time to Initial Objective Response	1.8 months Interval 1.7 to 2.3	1.9 months Interval 1.7 to 3.7

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Intent-to-treat analysis set

The resection rate was defined as the percentage of participants with a surgical procedure that resulted in partial reduction or complete eradication of all metastatic disease.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=142 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=143 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Resection Rate	12.68 percentage of participants Interval 7.69 to 19.29	11.19 percentage of participants Interval 6.53 to 17.53

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Wild-type RAS Efficacy Analysis Set, defined as a subset of Wild-type KRAS Exon 2 Efficacy Analysis Set including all randomized participants with wild-type KRAS exon 2, 3, 4, NRAS exon 2, 3, and 4.

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=88 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=82 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Progression-free Survival (PFS) in Participants With Wild-type Rat Sarcoma Viral Oncogene Homolog (RAS)	13.0 months Interval 10.9 to 15.1	9.5 months Interval 9.0 to 12.7

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Wild-type RAS/BRAF Efficacy Analysis Set was defined as a subset of Wild-type KRAS Exon 2 Efficacy Analysis Set with wild-type KRAS exon 2, 3, and 4, NRAS exon 2, 3, 4, and BRAF exon 15.

PFS was defined as the time from the date of randomization to the date of first disease progression, or death within 60 days after the last evaluable tumor assessment or randomization date (whichever was later). Participants not meeting the criteria by the cutoff date were censored at the last evaluable tumor assessment date. Tumor response was evaluated by the investigator per modified Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0 every 8 weeks until radiographic disease progression. Progression is defined as at least a 20% increase in the size of target lesions, unequivocal progression of existing non-target lesions, or any new lesions.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=77 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=79 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Progression-free Survival (PFS) in Participants With Wild-type RAS / V-raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)	13.1 months Interval 10.9 to 15.8	9.7 months Interval 7.9 to 12.7

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Wild-type RAS Efficacy Analysis Set, defined as a subset of Wild-type KRAS Exon 2 Efficacy Analysis Set including all randomized participants with wild-type KRAS exon 2, 3, 4, NRAS exon 2, 3, and 4.

Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=88 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=82 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Overall Survival in Participants With Wild-type RAS	NA months Interval 28.8 to Could not be estimated due to the low number of events	29.0 months Interval 24.3 to Could not be estimated due to the low number of events

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Wild-type RAS/BRAF Efficacy Analysis Set was defined as a subset of Wild-type KRAS Exon 2 Efficacy Analysis Set with wild-type KRAS exon 2, 3, and 4, NRAS exon 2, 3, 4, and BRAF exon 15.

Overall survival was defined as the time from randomization to the date of death, with participants alive or lost to follow-up at the analysis data cutoff date censored at their last contact date.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=77 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=79 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Overall Survival in Participants With Wild-type RAS / BRAF	NA months Could not be estimated due to the low number of events	29.0 months Interval 24.3 to Could not be estimated due to the low number of events

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Wild-type RAS Investigator Tumor Response Analysis Set, defined as the subset of participants in the Wild-type RAS Efficacy Analysis Set who had at least 1 unidimensionally measurable lesion per modified RECIST 1.0 per the local investigator.

Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met.

Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=88 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=81 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Percentage of Participants With an Objective Response for Participants With Wild-type RAS	63.64 percentage of participants Interval 52.69 to 73.63	60.49 percentage of participants Interval 49.01 to 71.19

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 30 May 2012; median follow-up time was 60 weeks.

Population: Wild-type RAS/BRAF Investigator Tumor Response Analysis Set, defined as the subset of participants in the Wild-type RAS/BRAF Efficacy Analysis Set who had at least 1 unidimensionally measurable lesion per modified RECIST 1.0 per the local investigator.

Objective response was defined as having a confirmed complete response (CR) or partial response (PR) during first-line treatment, based on the investigator's review of scans using a modified-RECIST v1.0. A complete or partial response was confirmed no less than 4-weeks after the criteria for response were first met. Complete Response: Disappearance of all target and non-target lesions and no new lesions. Partial Response: At least a 30% decrease in the sum of the longest diameter (SLD) of target lesions and no progression of non-target lesions and no new lesions, or the disappearance of all target lesions with persistence of one or more non-target lesion(s) not qualifying for either CR or progressive disease and no new lesions.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=77 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=78 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Percentage of Participants With an Objective Response for Participants With Wild-type RAS / BRAF	63.64 percentage of participants Interval 51.88 to 74.3	61.54 percentage of participants Interval 49.83 to 72.34

SECONDARY outcome

Timeframe: The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus mFOLFOX arm and 7.3 months for Bevacizumab Plus mFOLFOX6 arm.

Population: Safety analysis set, which included all randomized participants who received at least 1 dose of protocol treatment (ie, panitumumab, bevacizumab, or any component of mFOLFOX6).

Severity was graded using Common Terminology Criteria for Adverse Events (CTCAE) v3.0, with the exception of some dermatology/skin adverse events that were graded using CTCAE v3.0 with modifications. Fatal adverse events are classified as grade 5. Serious adverse events include any event that is fatal, life threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, a congenital anomaly/birth defect, or other significant medical hazard. Treatment-related AEs were those that the investigator considered a reasonable possibility that might have been caused by study drug.

Outcome measures

Measure	Panitumumab Plus mFOLFOX6 n=139 Participants Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=139 Participants Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Number of Participants With Adverse Events (AEs) AE with worst grade of 3	88 participants	78 participants
Number of Participants With Adverse Events (AEs) Any adverse event (AE)	139 participants	139 participants
Number of Participants With Adverse Events (AEs) AE with worst grade of 4	31 participants	28 participants
Number of Participants With Adverse Events (AEs) AE with worst grade of 5	7 participants	9 participants
Number of Participants With Adverse Events (AEs) Serious adverse event (SAE)	61 participants	53 participants
Number of Participants With Adverse Events (AEs) AE leading to discontinuation of study drug	34 participants	37 participants
Number of Participants With Adverse Events (AEs) Any treatment-related adverse event (TRAE)	138 participants	136 participants
Number of Participants With Adverse Events (AEs) Treatment-related AE with worst grade of 3	92 participants	77 participants
Number of Participants With Adverse Events (AEs) Treatment-related AE with worst grade of 4	24 participants	25 participants
Number of Participants With Adverse Events (AEs) Treatment-related AE with worst grade of 5	3 participants	2 participants
Number of Participants With Adverse Events (AEs) Serious treatment-related adverse event	37 participants	28 participants
Number of Participants With Adverse Events (AEs) TRAE leading to discontinuation of study drug	28 participants	29 participants

Adverse Events

Panitumumab Plus mFOLFOX6

Serious events: 61 serious events

Other events: 139 other events

Deaths: 0 deaths

Bevacizumab Plus mFOLFOX6

Serious events: 53 serious events

Other events: 139 other events

Deaths: 0 deaths

Serious adverse events

Measure	Panitumumab Plus mFOLFOX6 n=139 participants at risk Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=139 participants at risk Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Blood and lymphatic system disorders Febrile neutropenia	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Blood and lymphatic system disorders Leukopenia	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Blood and lymphatic system disorders Neutropenia	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Cardiac disorders Acute coronary syndrome	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Cardiac disorders Cardiac arrest	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Cardiac disorders Cardio-respiratory arrest	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Cardiac disorders Myocardial infarction	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Abdominal pain	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Anal fistula	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Colitis	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Constipation	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Diarrhoea	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Gastritis	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Gastrointestinal disorder	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Gastrointestinal perforation	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Gastrooesophageal reflux disease	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Ileus	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Inguinal hernia	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Intestinal obstruction	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Intestinal perforation	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Large intestinal obstruction	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Melaena	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Nausea	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Oesophagitis	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Rectal perforation	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Small intestinal perforation	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Stomatitis	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Vomiting	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Adverse drug reaction	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Chills	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Fatigue	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders General physical health deterioration	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Mucosal inflammation	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Non-cardiac chest pain	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Pyrexia	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Thrombosis in device	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Immune system disorders Anaphylactic reaction	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Immune system disorders Hypersensitivity	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Anal abscess	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Device related sepsis	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Endocarditis	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Escherichia bacteraemia	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Herpes zoster oticus	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Infection	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Infusion site infection	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Meningoencephalitis herpetic	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Orchitis	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Perirectal abscess	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Peritonitis	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Pneumonia	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Postoperative wound infection	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Sepsis	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Septic shock	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Subcutaneous abscess	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Urinary tract infection	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Injury, poisoning and procedural complications Ankle fracture	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Injury, poisoning and procedural complications Face injury	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Injury, poisoning and procedural complications Subdural haematoma	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Injury, poisoning and procedural complications Toxicity to various agents	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Injury, poisoning and procedural complications Wound haemorrhage	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Investigations Eastern Cooperative Oncology Group performance status worsened	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Decreased appetite	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Dehydration	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Hyperglycaemia	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Hyperkalaemia	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Hypokalaemia	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Bone pain	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Groin pain	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Trismus	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal cancer	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Convulsion	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Syncope	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Transient ischaemic attack	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Vertebrobasilar insufficiency	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Psychiatric disorders Mood altered	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Psychiatric disorders Panic attack	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Psychiatric disorders Substance abuse	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Renal and urinary disorders Renal failure	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Renal and urinary disorders Renal failure acute	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Renal and urinary disorders Ureteric obstruction	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Reproductive system and breast disorders Epididymitis	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Reproductive system and breast disorders Pelvic pain	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Pneumonia aspiration	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	4.3% 6/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Pulmonary venous thrombosis	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Nail bed inflammation	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Rash	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Deep vein thrombosis	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Intra-abdominal haematoma	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Jugular vein thrombosis	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Superior vena cava syndrome	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Thrombophlebitis superficial	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Thrombosis	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.

Other adverse events

Measure	Panitumumab Plus mFOLFOX6 n=139 participants at risk Participants received 6 mg/kg panitumumab administered by intravenous (IV) infusion and mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.	Bevacizumab Plus mFOLFOX6 n=139 participants at risk Participants received 5 mg/kg bevacizumab administered by IV infusion and the mFOLFOX6 chemotherapy regimen on Day 1 of every 14-day cycle.
Gastrointestinal disorders Abdominal pain	18.0% 25/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	18.0% 25/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Blood and lymphatic system disorders Anaemia	17.3% 24/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	14.4% 20/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Blood and lymphatic system disorders Leukopenia	7.2% 10/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Blood and lymphatic system disorders Neutropenia	45.3% 63/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	47.5% 66/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Blood and lymphatic system disorders Thrombocytopenia	24.5% 34/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	12.2% 17/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Eye disorders Conjunctivitis	11.5% 16/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Eye disorders Lacrimation increased	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	4.3% 6/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Eye disorders Vision blurred	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Abdominal pain upper	7.9% 11/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	8.6% 12/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Cheilitis	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Constipation	31.7% 44/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	31.7% 44/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Diarrhoea	60.4% 84/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	60.4% 84/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Dyspepsia	10.1% 14/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	10.8% 15/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Flatulence	7.2% 10/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	4.3% 6/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Haemorrhoids	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Nausea	54.0% 75/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	59.7% 83/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Rectal haemorrhage	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	4.3% 6/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Stomatitis	33.1% 46/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	22.3% 31/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Gastrointestinal disorders Vomiting	30.9% 43/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	27.3% 38/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Asthenia	36.0% 50/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	31.7% 44/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Chills	7.9% 11/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	8.6% 12/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Fatigue	36.0% 50/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	46.8% 65/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Mucosal inflammation	35.3% 49/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	15.1% 21/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Oedema peripheral	12.9% 18/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	9.4% 13/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Pyrexia	15.1% 21/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	21.6% 30/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
General disorders Temperature intolerance	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	7.9% 11/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Bronchitis	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Nasopharyngitis	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Paronychia	18.0% 25/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Respiratory tract infection	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	3.6% 5/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Rhinitis	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	3.6% 5/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Upper respiratory tract infection	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Infections and infestations Urinary tract infection	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	7.2% 10/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Injury, poisoning and procedural complications Infusion related reaction	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	4.3% 6/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Investigations Platelet count decreased	7.2% 10/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	3.6% 5/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Investigations Weight decreased	22.3% 31/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	11.5% 16/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Investigations Weight increased	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Decreased appetite	40.3% 56/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	31.7% 44/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Dehydration	12.9% 18/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	7.2% 10/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Hypoalbuminaemia	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Hypocalcaemia	8.6% 12/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	3.6% 5/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Hypokalaemia	27.3% 38/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	12.9% 18/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Metabolism and nutrition disorders Hypomagnesaemia	41.0% 57/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Arthralgia	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	10.1% 14/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Back pain	8.6% 12/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	10.1% 14/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Muscular weakness	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Musculoskeletal chest pain	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Neck pain	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Musculoskeletal and connective tissue disorders Pain in extremity	8.6% 12/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	12.9% 18/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Dizziness	11.5% 16/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	10.8% 15/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Dysaesthesia	9.4% 13/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	16.5% 23/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Dysgeusia	22.3% 31/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	19.4% 27/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Headache	8.6% 12/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	10.8% 15/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Neuropathy peripheral	31.7% 44/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	32.4% 45/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Neurotoxicity	10.8% 15/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	9.4% 13/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Paraesthesia	18.0% 25/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	22.3% 31/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Peripheral sensory neuropathy	17.3% 24/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	17.3% 24/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Nervous system disorders Polyneuropathy	12.9% 18/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	11.5% 16/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Psychiatric disorders Anxiety	7.2% 10/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Psychiatric disorders Insomnia	10.1% 14/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	13.7% 19/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Renal and urinary disorders Proteinuria	10.8% 15/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	7.9% 11/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Cough	12.2% 17/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	9.4% 13/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Dysphonia	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Dyspnoea	10.8% 15/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	12.9% 18/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Epistaxis	20.9% 29/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	23.0% 32/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	8.6% 12/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Respiratory, thoracic and mediastinal disorders Rhinorrhoea	2.2% 3/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	9.4% 13/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Acne	25.2% 35/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Alopecia	18.0% 25/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	15.1% 21/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Dermatitis acneiform	19.4% 27/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Dry skin	38.1% 53/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	8.6% 12/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Erythema	7.9% 11/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Exfoliative rash	7.9% 11/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	1.4% 2/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Hypertrichosis	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Nail disorder	8.6% 12/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	4.3% 6/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	15.8% 22/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	10.1% 14/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Pruritus	11.5% 16/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	2.9% 4/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Rash	61.9% 86/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	6.5% 9/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Skin fissures	20.9% 29/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Skin and subcutaneous tissue disorders Skin toxicity	5.8% 8/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	0.00% 0/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Deep vein thrombosis	3.6% 5/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	7.2% 10/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Haematoma	0.72% 1/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Hypertension	4.3% 6/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	25.2% 35/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.
Vascular disorders Hypotension	5.0% 7/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.	4.3% 6/139 • The time frame for adverse event reporting is from the first dose date to 30 days since the last dose date. The median time frame is 8.0 months for Panitumumab Plus Chemotherapy arm and 7.3 months for Bevacizumab Plus Chemotherapy arm. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency in either treatment arm.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Results disclosure agreements

• Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
• Publication restrictions are in place

Restriction type: OTHER